Pasar al contenido principal

ESTUDIO DEL METABOLISMO PARA LA APLICACION DE MEDICINA DE PRECISION EN CANCER DE PROSTATA METASTATICO

SAF2016-79381-R

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2016
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The immunosuppressive effect of the tick protein, Salp15, is long-lasting and persists in a murine model of hematopoietic transplant

  • Tomás-Cortázar, Julen
  • Martín-Ruiz, Itziar
  • Barriales, Diego
  • Pascual-Itoiz, Miguel Ángel
  • Gutiérrez de Juan, Virginia
  • Caro-Maldonado, Alfredo
  • Merino, Nekane
  • Marina, Alberto
  • Blanco, Francisco J.
  • Flores, Juana María
  • Sutherland, James D.
  • Barrio, Rosa
  • Rojas, Adriana
  • Martínez-Chantar, María Luz
  • Carracedo, Arkaitz
  • Simó, Carolina
  • García-Cañas, Virginia
  • Abecia, Leticia
  • Lavín, José Luis
  • Aransay, Ana M.
  • Rodríguez, Héctor
  • Anguita, Juan
Salp15, a salivary protein of Ixodes ticks, inhibits the activation of naïve CD4 T cells. Treatment with Salp15 results in the inhibition of early signaling events and the production of the autocrine growth factor, interleukin-2. The fate of the CD4 T cells activated in the presence of Salp15 or its long-term effects are, however, unknown. We now show that Salp15 binding to CD4 is persistent and induces a long-lasting immunomodulatory effect. The activity of Salp15 results in sustained diminished cross-antigenic antibody production even after interruption of the treatment with the protein. Transcriptionally, the salivary protein provokes an acute effect that includes known activation markers, such as Il2 or Cd44, and that fades over time. The long-term effects exerted by Salp15 do not involve the induction of either anergy traits nor increased populations of regulatory T cells. Similarly, the treatment with Salp15 does not result in B cell anergy or the generation of myeloid suppressor cells. However, Salp15 induces the increased expression of the ectoenzyme, CD73, in regulatory T cells and increased production of adenosine. Our study provides a profound characterization of the immunomodulatory activity of Salp15 and suggests that its long-term effects are due to the specific regulation of CD73. Introduction, Supported by grants from the Department of Education of the Basque Government (PI2013-49 to JA and PI2012-42 to RB). JA is funded by the European Union (Grant Agreement number 602272). AMA and JLL’s work was supported by the Basque Department of Industry, Tourism and Trade (Etortek and Elkartek Programs), the Innovation Technology Department of Bizkaia and the CIBERehd Network. The work of AC is supported by a Ramón y Cajal award, the Basque Department of Industry, Tourism and Trade (Etortek), ISCIII (PI13/00031), FERO VIII Fellowship, the BBVA foundation, MINECO (SAF2016-79381-R) and the European Research Council Starting Grant (336343). CIBERonc was co-funded with FEDER funds. AC-M was funded by a Juan de la Cierva program award and the European Union MSCA program (CIG 660191). RB was funded by MINECO grants BFU2011-25986 and BFU2014-52282-P and the Consolider Program (BFU2014-57703-REDC). FJB was funded by a MINECO grant (CTQ2014-56966-R). D.B. is funded by a MINECO FPI fellowship. We thank the MINECO for the Severo Ochoa Excellence accreditation (SEV-2016-0644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Multiplex SERS Detection of Metabolic Alterations in Tumor Extracellular Media

  • Plou, Javier
  • García, Isabel
  • Charconnet, Mathias
  • Astobiza, Ianire
  • García Astrain, Clara
  • Matricardi, Cristiano
  • Mihi, Agustín
  • Carracedo, Arkaitz
  • Liz-Marzán, Luis Manuel
The composition and intercellular interactions of tumor cells in the tissues dictate the biochemical and metabolic properties of the tumor microenvironment. The metabolic rewiring has a profound impact on the properties of the microenvironment, to an extent that monitoring such perturbations could harbor diagnostic and therapeutic relevance. A growing interest in these phenomena has inspired the development of novel technologies with sufficient sensitivity and resolution to monitor metabolic alterations in the tumor microenvironment. In this context, surface‐enhanced Raman scattering (SERS) can be used for the label‐free detection and imaging of diverse molecules of interest among extracellular components. Herein, the application of nanostructured plasmonic substrates comprising Au nanoparticles, self‐assembled as ordered superlattices, to the precise SERS detection of selected tumor metabolites, is presented. The potential of this technology is first demonstrated through the analysis of kynurenine, a secreted immunomodulatory derivative of the tumor metabolism and the related molecules tryptophan and purine derivatives. SERS facilitates the unambiguous identification of trace metabolites and allows the multiplex detection of their characteristic fingerprints under different conditions. Finally, the effective plasmonic SERS substrate is combined with a hydrogel‐based three‐dimensional cancer model, which recreates the tumor microenvironment, for the real‐time imaging of metabolite alterations and cytotoxic effects on tumor cells., J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.‐M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM‐2017‐0720). C.G.‐A. acknowledges a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2016‐28887). The authors thank Dr. J. Calvo and Dr. D. Otaegui at CIC biomaGUNE for support with LC/ESI‐HRMS measurements. The work of A.C. was supported by the Basque Department of Industry, Tourism and Trade (Elkartek), and the department of education (IKERTALDE IT1106‐16, also participated by A. Gomez‐Muñoz), the BBVA foundation, the MINECO (SAF2016‐79381‐R (FEDER/EU); Severo Ochoa Excellence Program SEV‐2016‐0644‐18‐1; Excellence Networks SAF2016‐81975‐REDT), European Training Networks Project (H2020‐MSCA‐ITN‐308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (HR17‐00094), and the European Research Council (starting Grant 336343, PoC 754627). CIBERONC was co‐funded with FEDER funds and funded by ISCIII. A.M. acknowledges funding from the European Research Council (Consolidator Grant 819242) and the Spanish Ministry of Science, Innovation and Universities for the excellence program SEV‐2015‐0496.J.P. acknowledges an FPU fellowship from the Spanish Ministry of Science, Innovation and Universities. L.M.L.‐M. acknowledges funding from the European Research Council (ERC AdG 787510, 4DbioSERS) and the Maria de Maeztu Units of Excellence Program from the Spanish State Research Agency (Grant No. MDM‐2017‐0720). C.G.‐A. acknowledges a Juan de la Cierva Fellowship from the Spanish Ministry of Science, Innovation and Universities (FJCI‐2016‐28887). The authors thank Dr. J. Calvo and Dr. D. Otaegui at CIC biomaGUNE for support with LC/ESI‐HRMS measurements. The work of A.C. was supported by the Basque Department of Industry, Tourism and Trade (Elkartek), and the department of education (IKERTALDE IT1106‐16, also participated by A. Gomez‐Muñoz), the BBVA foundation, the MINECO (SAF2016‐79381‐R (FEDER/EU); Severo Ochoa Excellence Program SEV‐2016‐0644‐18‐1; Excellence Networks SAF2016‐81975‐REDT), European Training Networks Project (H2020‐MSCA‐ITN‐308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (HR17‐00094), and the European Research Council (starting Grant 336343, PoC 754627). CIBERONC was co‐funded with FEDER funds and funded by ISCIII. A.M. acknowledges funding from the European Research Council (Consolidator Grant 819242) and the Spanish Ministry of Science, Innovation and Universities for the excellence program SEV‐2015‐0496., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic and Functional Regulation of TRIB1 Contributes to Prostate Cancer Pathogenesis

  • Shahrouzi, Parastoo
  • Astobiza, Ianire
  • Cortázar, Ana R.
  • Torrano, Verónica
  • Macchia, Alice
  • Flores, Juana María
  • Niespolo, Chiara
  • Mendizábal, Isabel
  • Caloto, Rubén
  • Ercilla, Amaia
  • Camacho, Laura
  • Arreal, Leire
  • Bizkarguenaga, Maider
  • Martínez-Chantar, María Luz
  • Bustelo, Xosé R.
  • Berra, Edurne
  • Kiss-Toth, Endre
  • Velasco, Guillermo
  • Zabala-Letona, Amaia
  • Carracedo, Arkaitz
© 2020 by the authors., Prostate cancer is the most frequent malignancy in European men and the second worldwide. One of the major oncogenic events in this disease includes amplification of the transcription factor cMYC. Amplification of this oncogene in chromosome 8q24 occurs concomitantly with the copy number increase in a subset of neighboring genes and regulatory elements, but their contribution to disease pathogenesis is poorly understood. Here we show that TRIB1 is among the most robustly upregulated coding genes within the 8q24 amplicon in prostate cancer. Moreover, we demonstrate that TRIB1 amplification and overexpression are frequent in this tumor type. Importantly, we find that, parallel to its amplification, TRIB1 transcription is controlled by cMYC. Mouse modeling and functional analysis revealed that aberrant TRIB1 expression is causal to prostate cancer pathogenesis. In sum, we provide unprecedented evidence for the regulation and function of TRIB1 in prostate cancer., We are grateful to the Carracedo lab for valuable input, to Ana M. Aransay and F. Elortza for technical advice. P.S. was funded by the European Training Networks Project (H2020-MSCA-ITN-308 2016 721532). V.T. is funded by Fundación Vasca de Innovación e Investigación Sanitarias, BIOEF (BIO15/CA/052), the AECC J.P. Bizkaia, the Basque Department of Health (2016111109) and the MICINN RTI2018-097267-B-I00. A. Macchia was funded by a FPI predoctoral fellowship from MICINN (PRE2018-083607). EB is funded by the MICINN (BFU2016-76872-R (FEDER/EU), PID2019-108112RB-I00, Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2017-90794-REDT). The work of A. Carracedo is supported by the Basque Department of Industry, Tourism and Trade (Elkartek), the department of education (IKERTALDE IT1106-16) and health (RIS3), the BBVA foundation and the MICINN (SAF2016-79381-R (FEDER/EU; PID2019-108787RB-I00) Severo Ochoa Excellence Accreditation SEV-2016-0644 and Excellence Networks SAF2016-81975-REDT and RED2018-102769-T), European Training Networks Project (H2020-MSCA-ITN-308 2016 721532), the AECC (IDEAS175CARR, GCTRA18006CARR), La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/ and the European Research Council (Starting Grant 336343, Consolidator Grant 819242). CIBERONC was co-funded with FEDER funds and funded by ISCIII.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer

  • Zabala-Letona, Amaia
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Martín Martín, Natalia
  • Fernández Ruiz, Sonia
  • Sutherland, James D.|||0000-0003-3229-793X
  • Clasquin, Michelle
  • Tomás Cortázar, Julen
  • Jiménez, José
  • Torres Ramírez, Inés Ma. de
  • Quang, Phong
  • Ximénez-Embún, Pilar|||0000-0002-2582-9443
  • Bago, Ruzica
  • Ugalde Olano, Aitziber
  • Loizaga Iriarte, Ana
  • Lacasa-Viscasillas, Isabel
  • Unda, Miguel
  • Torrano, Verónica
  • Cabrera, Diana
  • van Liempd, Sebastiaan M.
  • Cendon, Ylenia
  • Castro, Elena|||0000-0002-3691-6454
  • Murray, Stuart
  • Revandkar, Ajinkya
  • Alimonti, Andrea
  • Zhang, Yinan
  • Barnett, Amelia
  • Lein, Gina
  • Pirman, David
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Arreal, Leire
  • Prudkin, Ludmila
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel-Jimenez, Lorea
  • Zúñiga-García, Patricia
  • Fernández Domínguez, Itziar
  • Piva, Marco
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Sánchez Mosquera, Pilar
  • Castillo Martín, Mireia
  • Serra, Violeta|||0000-0001-6620-1065
  • Beraza, Naiara
  • Gentilella, Antonio|||0000-0002-6830-2086
  • Thomas, George|||0000-0002-1236-1714
  • Azkargorta, Mikel
  • Elortza, Felix|||0000-0001-8839-5438
  • Farràs, Rosa
  • Olmos, David
  • Efeyan, Alejo
  • Anguita, Juan
  • Muñoz, Javier|||0000-0003-3288-3496
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Barrio, Rosa|||0000-0002-9663-0669
  • Macarulla Mercadé, Teresa|||0000-0002-5856-4082
  • Mato, José M.
  • Martínez Chantar, Maria L.
  • Cordon Cardo, Carlos
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Marks, Kevin
  • Baselga Torres, Josep
  • Tabernero, Josep|||0000-0002-2495-8139
  • Nuciforo, Paolo|||0000-0003-1380-0990
  • Manning, Brendan D.
  • Marjon, Katya
  • Carracedo, Arkaitz|||0000-0001-5957-1260
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. Through the use of integrative metabolomics in a mouse model and human biopsies of prostate cancer, we identified alterations in tumours impacting on the production of decarboxylated S-adenosylmethionine (dcSAM) and polyamine synthesis. Mechanistically, this metabolic rewiring stems from mTORC1-dependent regulation of S-adenosylmethionine decarboxylase 1 (AMD1) stability. This novel molecular regulation was validated in murine and human cancer specimens. AMD1 was upregulated in prostate cancer specimens with activated mTORC1. Conversely, samples from a clinical trial with the mTORC1 inhibitor everolimus exhibited a predominant decrease in AMD1 immunoreactivity that was associated to a decrease in proliferation, in line with the requirement of dcSAM production for oncogenicity. These findings provide fundamental information about the complex regulatory landscape controlled by mTORC1 to integrate and translate growth signals into an oncogenic metabolic program.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Low-dose statin treatment increases prostate cancer aggressiveness

  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Camacho, Laura
  • Zabala-Letona, Amaia
  • Torrano, Verónica
  • Fernández Ruiz, Sonia
  • Zamacola, Kepa
  • Arreal, Leire
  • Valcarcel-Jimenez, Lorea
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Flores, Juana M.|||0000-0002-7995-4426
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Zúñiga-García, Patricia
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Guillaumond, Fabienne
  • Cabrera, Diana
  • Falcón-Pérez, Juan M.|||0000-0003-3133-0670
  • Aransay, Ana M.|||0000-0002-8271-612X
  • Gomez Muñoz, Antonio|||0000-0002-2539-016X
  • Olivan, Mireia|||0000-0002-8464-0827
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Carracedo, Arkaitz|||0000-0001-5957-1260
Prostate cancer is diagnosed late in life, when co-morbidities are frequent. Among them, hypertension, hypercholesterolemia, diabetes or metabolic syndrome exhibit an elevated incidence. In turn, prostate cancer patients frequently undergo chronic pharmacological treatments that could alter disease initiation, progression and therapy response. Here we show that treatment with anti-cholesterolemic drugs, statins, at doses achieved in patients, enhance the pro-tumorigenic activity of obesogenic diets. In addition, the use of a mouse model of prostate cancer and human prostate cancer xenografts revealed that in vivo simvastatin administration alone increases prostate cancer aggressiveness. In vitro cell line systems supported the notion that this phenomenon occurs, at least in part, through the direct action on cancer cells of low doses of statins, in range of what is observed in human plasma. In sum, our results reveal a prostate cancer experimental system where statins exhibit an undesirable effect, and warrant further research to address the relevance and implications of this observation in human prostate cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer

  • Hermanova, Ivana
  • Zúñiga-García, Patricia
  • Caro-Maldonado, Alfredo|||0000-0002-5431-7949
  • Fernandez-Ruiz, Sonia
  • Salvador Velez, Fernando Maria|||0000-0002-0546-1354
  • Martín-Martín, Natalia|||0000-0002-2527-429X
  • Zabala-Letona, Amaia
  • Nuñez-Olle, Marc|||0000-0002-3593-2591
  • Torrano, Verónica
  • Camacho, Laura
  • Lizcano de Vega, José Miguel|||0000-0002-3154-5383
  • Talamillo, Ana
  • Carreira, Suzanne|||0000-0002-5077-5379
  • Gurel, Bora|||0000-0002-5018-8078
  • Cortazar, Ana Rosa|||0000-0002-7082-5695
  • Guiu, Marc|||0000-0002-7083-986X
  • López, Jose I.|||0000-0003-0842-5348
  • Martinez-Romero, Anabel
  • Astobiza, Ianire|||0000-0002-7142-7066
  • Valcarcel, Lorea|||0000-0002-7309-9924
  • Lorente, Mar|||0000-0003-0982-0956
  • Arruabarrena-Aristorena, Amaia|||0000-0002-1636-3944
  • Velasco, Guillermo|||0000-0002-1994-2386
  • Gomez Muñoz, Antonio|||0000-0002-2539-016X
  • Suárez-Cabrera, Cristian|||0000-0003-1897-1596
  • Lodewijk, Iris
  • Flores, Juana M.|||0000-0002-7995-4426
  • Sutherland, James D.|||0000-0003-3229-793X
  • Barrio, Rosa|||0000-0002-9663-0669
  • de Bono, Johann S.|||0000-0002-2034-595X
  • Paramio, Jesús M.|||0000-0001-7520-3177
  • Trka, Jan|||0000-0002-9527-8608
  • Graupera, Mariona|||0000-0003-4608-4185
  • Gomis, Roger R.|||0000-0001-6473-2858
  • Carracedo, Arkaitz|||0000-0001-5957-1260
This study unravels an unprecedented murine model of lethal metastatic prostate cancer, based on the combined deletion of Pten and Lkb1. Importantly, minimal activity of LKB1 is sufficient to hamper prostate cancer cell aggressiveness, thus redefining the relationship between gene dosage and tumor suppression. Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1 K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.